These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 28341889)

  • 1. Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.
    Mizuno M; Suzuki Y; Ito Y
    Clin Exp Nephrol; 2018 Feb; 22(1):3-14. PubMed ID: 28341889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecules Great and Small: The Complement System.
    Mathern DR; Heeger PS
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1636-50. PubMed ID: 25568220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel roles of complement in renal diseases and their therapeutic consequences.
    Wada T; Nangaku M
    Kidney Int; 2013 Sep; 84(3):441-50. PubMed ID: 23615508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement and kidney disease.
    Cook HT
    Curr Opin Nephrol Hypertens; 2013 May; 22(3):295-301. PubMed ID: 23508058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement and Complement Targeting Therapies in Glomerular Diseases.
    Andrighetto S; Leventhal J; Zaza G; Cravedi P
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31888179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015.
    Noris M; Remuzzi G
    Am J Kidney Dis; 2015 Aug; 66(2):359-75. PubMed ID: 26032627
    [No Abstract]   [Full Text] [Related]  

  • 7. Complement deposition in glomerular diseases.
    di Belgiojoso GB; Tarantino A; Durante A; Guerra L
    Proc Eur Dial Transplant Assoc; 1975; 11():515-21. PubMed ID: 1105561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).
    Sethi S; Fervenza FC
    Semin Thromb Hemost; 2014 Jun; 40(4):416-21. PubMed ID: 24799306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes in the complement system in membranoproliferative glomerulonephritis].
    Yurova VA; Bobrova LA; Kozlovskaya NL; Korotchaeva YV; Serova AG; Kozlov LV; Andina SS; Demyanova KA; Kuchieva AM; Roshchupkina SV
    Ter Arkh; 2017; 89(6):69-77. PubMed ID: 28745692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All Things Complement.
    Thurman JM; Nester CM
    Clin J Am Soc Nephrol; 2016 Oct; 11(10):1856-1866. PubMed ID: 27340286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complement cascade and renal disease.
    Kościelska-Kasprzak K; Bartoszek D; Myszka M; Zabińska M; Klinger M
    Arch Immunol Ther Exp (Warsz); 2014 Feb; 62(1):47-57. PubMed ID: 24030732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The complement system: pathophysiology and clinical relevance.
    Speth C; Würzner R; Stoiber H; Dierich MP
    Wien Klin Wochenschr; 1999 May; 111(10):378-91. PubMed ID: 10413831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C4 Glomerulopathy: A Disease Entity Associated With C4d Deposition.
    Sethi S; Quint PS; O'Seaghdha CM; Fervenza FC; Bijol V; Dorman A; Dasari S; Smith RJ; Kurtin PJ; Rennke HG
    Am J Kidney Dis; 2016 Jun; 67(6):949-53. PubMed ID: 26896898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
    Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
    Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective complement inhibitory function predisposes to renal disease.
    Java A; Atkinson J; Salmon J
    Annu Rev Med; 2013; 64():307-24. PubMed ID: 23121180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the complement cascade: novel treatments coming down the pike.
    Thurman JM; Le Quintrec M
    Kidney Int; 2016 Oct; 90(4):746-52. PubMed ID: 27325183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of properdin in complement-mediated kidney diseases.
    van Essen MF; Ruben JM; de Vries APJ; van Kooten C;
    Nephrol Dial Transplant; 2019 May; 34(5):742-750. PubMed ID: 30053164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of C3 glomerulopathy with complement blockers.
    Vivarelli M; Emma F
    Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement in Non-Antibody-Mediated Kidney Diseases.
    Angeletti A; Reyes-Bahamonde J; Cravedi P; Campbell KN
    Front Med (Lausanne); 2017; 4():99. PubMed ID: 28748184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.